for this devastating disease. We have identified inhibition of hypoxia-inducible factor (HIF) hydroxylases (PHDs) as a promising non-toxic strategy to target leukaemic stem cells by modulating HIF signalling (Lawson/Holt-Martyn et al ., Nature Cancer , 2024; Vukovic et al ., Journal of Experimental Medicine , 2015; Vukovic et al ., Blood , 2016). The postholder will investigate how inactivation of PHDs and related enzymes impacts AML biology, identify AML subtypes sensitive to these interventions, evaluate novel small-molecule inhibitors in vivo , and discover synthetic lethal vulnerabilities and resistance mechanisms to inform optimal combination strategies and overcome therapeutic resistance. About you The successful candidate must have: PhD in hypoxia biology, biochemistry, cell biology, molecular biology, stem cell biology, oncology or chemical biology. Significant experience in hypoxia biology/biochemistry, stem cell biology, and cancer research. Previous postdoctoral experience in hypoxia and/or leukaemia biology. Candidates who are nearing completion of their PhD may apply, but confirmation on awarded PhD is required within 6 months of employment. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years. For general information on Postdocs at The ICR, more information can be found here . Department/Directorate Information: The Haemato-Oncology Group specialises in understanding and targeting leukaemic stem cells, which are responsible for AML initiation, disease progression, relapse, and resistance to conventional therapies. Our group focuses on discovering cures for acute myeloid leukaemia with an aim to identify novel therapeutic targets for selective elimination of LSCs, without disrupting normal haematopoiesis. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Professor Kamil Kranc via email kamil.kranc@icr.ac.uk

for this devastating disease. We have identified inhibition of hypoxia-inducible factor (HIF) hydroxylases (PHDs) as a promising non-toxic strategy to target leukaemic stem cells by modulating HIF signalling (Lawson/Holt-Martyn et al ., Nature Cancer , 2024; Vukovic et al ., Journal of Experimental Medicine , 2015; Vukovic et al ., Blood , 2016). The postholder will investigate how inactivation of PHDs and related enzymes impacts AML biology, identify AML subtypes sensitive to these interventions, evaluate novel small-molecule inhibitors in vivo , and discover synthetic lethal vulnerabilities and resistance mechanisms to inform optimal combination strategies and overcome therapeutic resistance. About you The successful candidate must have: PhD in hypoxia biology, biochemistry, cell biology, molecular biology, stem cell biology, oncology or chemical biology. Significant experience in hypoxia biology/biochemistry, stem cell biology, and cancer research. Previous postdoctoral experience in hypoxia and/or leukaemia biology. Candidates who are nearing completion of their PhD may apply, but confirmation on awarded PhD is required within 6 months of employment. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years. For general information on Postdocs at The ICR, more information can be found here . Department/Directorate Information: The Haemato-Oncology Group specialises in understanding and targeting leukaemic stem cells, which are responsible for AML initiation, disease progression, relapse, and resistance to conventional therapies. Our group focuses on discovering cures for acute myeloid leukaemia with an aim to identify novel therapeutic targets for selective elimination of LSCs, without disrupting normal haematopoiesis. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Professor Kamil Kranc via email kamil.kranc@icr.ac.uk